May 23, 2019: How CD4 variables over time affect anal cancer risk; when to consider anal pap smears for women; switching from E/C/F/TAF to ABC/3TC; new data on marijuana use among people with HIV.
More research is needed to understand the connections between HIV, mental health, and the neurocircuitry that controls executive function.
Switching HIV treatment regimens during the first trimester; drivers of viral breakthrough during pregnancy; HIV’s effect on liver risk after hepatitis C treatment; hepatic steatosis among young people with HIV.
Impact of intimate partner violence on PrEP attitudes among women; evolution of first-line HIV treatment failure rates; cumulative low-level viremia and virologic failure risk; HIV drug levels in breast milk versus plasma.
A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.
The most popular form of long-acting HIV treatment; telehealth for PrEP uptake among young MSM of color; PrEP awareness and usage among Rhode Island women; assessing cognitive benefits of switching off of efavirenz.
The skin cancer Kaposi Sarcoma (KS) is an HIV-related condition that primarily affects men, but a new cases series presented at IDWeek 2018 in San Francisco highlights the importance of studying women with KS.
In a study of more than 1,400 women living with HIV, nearly 30% did not achieve viral suppression and some groups of women had greater challenges with adherence and staying in care.
A newly published study suggests that women may respond differently than men to some HIV curative interventions that are currently under investigation or, perhaps, that an effective HIV cure for women could differ from a cure for men.